"Phase 2 trial" trang 1 - tải miễn phí từ tailieunhanh
Effcacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: A multicenter, prospective, single-arm, phase 2 trial

Effcacy and safety of pomalidomide and low-dose dexamethasone in Chinese patients with relapsed or refractory multiple myeloma: A multicenter, prospective, single-arm, phase 2 trial
9    14    1
Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: Study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)

Sintilimab plus nab-paclitaxel as second-line treatment for advanced biliary tract cancer: Study protocol for an investigator-initiated phase 2 trial (NapaSinti trial)
7    1    1
Optimal biological dose: A systematic review in cancer phase I clinical trials

Optimal biological dose: A systematic review in cancer phase I clinical trials
10    30    1
Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: A subgroup analysis of a randomized phase III trial

Efficacy and safety of concurrent chemoradiotherapy in ECOG 2 patients with locally advanced non-small-cell lung cancer: A subgroup analysis of a randomized phase III trial
10    96    0
Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled openlabel phase II trial

Stereotactic ablative body radiotherapy (SABR) combined with immunotherapy (L19-IL2) versus standard of care in stage IV NSCLC patients, ImmunoSABR: A multicentre, randomised controlled openlabel phase II trial
10    34    1
Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: A randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma

Patient-reported outcome (PRO) results from the AGITG DOCTOR trial: A randomised phase 2 trial of tailored neoadjuvant therapy for resectable oesophageal adenocarcinoma
11    17    1
Are participants concerned about privacy and security when using short message service to report product adherence in a rectal microbicide trial?

Are participants concerned about privacy and security when using short message service to report product adherence in a rectal microbicide trial?
8    1    1
A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial

A multicenter investigator-initiated Phase 2 trial of E7090 in patients with advanced or recurrent solid tumor with fibroblast growth factor receptor (FGFR) gene alteration: FORTUNE trial
7    2    1
The ASAMET trial: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients

The ASAMET trial: A randomized, phase II, double-blind, placebo-controlled, multicenter, 2 × 2 factorial biomarker study of tertiary prevention with low-dose aspirin and metformin in stage I-III colorectal cancer patients
9    56    1
Metastasis-directed therapy in castrationrefractory prostate cancer (MEDCARE): A non-randomized phase 2 trial

Metastasis-directed therapy in castrationrefractory prostate cancer (MEDCARE): A non-randomized phase 2 trial
7    52    0
Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial

Stereotactic radiotherapy on brain metastases with recent hemorrhagic signal: STEREO-HBM, a two-step phase 2 trial
9    45    0
A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: Design of the CARDAPAC study

A phase 2 randomized trial to evaluate the impact of a supervised exercise program on cardiotoxicity at 3 months in patients with HER2 overexpressing breast cancer undergoing adjuvant treatment by trastuzumab: Design of the CARDAPAC study
11    40    1
RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis

RECORD-4 multicenter phase 2 trial of second-line everolimus in patients with metastatic renal cell carcinoma: Asian versus non-Asian population subanalysis
4    74    1
Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2 - positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)

Ipilimumab or FOLFOX with Nivolumab and Trastuzumab in previously untreated HER2 - positive locally advanced or metastatic EsophagoGastric Adenocarcinoma - the randomized phase 2 INTEGA trial (AIO STO 0217)
10    49    1
Ruxolitinib in GvHD (RIG) study: A multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versushost disease (aGvHD) (NCT02396628)

Ruxolitinib in GvHD (RIG) study: A multicenter, randomized phase 2 trial to determine the response rate of Ruxolitinib and best available treatment (BAT) versus BAT in steroid-refractory acute graft-versushost disease (aGvHD) (NCT02396628)
8    66    1
Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: Study protocol of the target selection phase III CHIC-STS trial

Value of peri-operative chemotherapy in patients with CINSARC high-risk localized grade 1 or 2 soft tissue sarcoma: Study protocol of the target selection phase III CHIC-STS trial
8    80    1
Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): A multicenter, phase II trial

Optimal regimen of trastuzumab in combination with oxaliplatin/ capecitabine in first-line treatment of HER2-positive advanced gastric cancer (CGOG1001): A multicenter, phase II trial
9    59    1
Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouraciloxaliplatin—folinic acid (FOLFOX) for resectable esophageal and junctional cancer: The PROTECT-1402, randomized phase 2 trial

Preoperative chemoradiation with paclitaxel-carboplatin or with fluorouraciloxaliplatin—folinic acid (FOLFOX) for resectable esophageal and junctional cancer: The PROTECT-1402, randomized phase 2 trial
7    93    1
Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: A phase 2, multi-center, randomized, prospective, interventional trial

Study protocol for OptimalTTF-2: enhancing Tumor Treating Fields with skull remodeling surgery for first recurrence glioblastoma: A phase 2, multi-center, randomized, prospective, interventional trial
8    29    1
Randomized, placebo controlled, double blinded pilot superiority phase 2 trial to evaluate the effect of curcumin in moderate to severe asthmatics

Randomized, placebo controlled, double blinded pilot superiority phase 2 trial to evaluate the effect of curcumin in moderate to severe asthmatics
8    30    1